| 05.28.21 | J&J near FDA deal on Emergent plant restart; CDC mask guidelines not enough to motivate unvaccinated

Laden...

3 jaren geleden

Html
Tekst

How your smartwatch might detect an infection To view this email as a web page, click here

Webinar: Accelerating NASH Clinical Trials

Tuesday, June 15 | 10am ET / 7am PT

Join industry leaders for a webinar dedicated to overcoming key challenges presented in NASH drug development. We’ll explore key considerations for liver biopsy collection and interpretation, emerging non-invasive biomarkers, and the connection between clinical practice and drug development. Register now.

Editor's Note: Fierce COVID-19 Update will not publish on Monday in observance of the Memorial Day holiday, but we’ll be back in your inbox on Tuesday, June 1.

Today's Rundown

J&J homes in on manufacturing restart at Emergent plant behind 15M discarded COVID-19 doses More than just a step-tracker, smartwatches can predict blood test results and infections, study finds Working remotely helped FDA's CDER shape a new and improved workforce, director says. What now? UPDATED Coronavirus tracker: Most unvaccinated people say new CDC mask guidelines aren't enough of an incentive COVID-19 tracker: J&J shot authorized in UK, Mexico; China's Sinopharm releases long-awaited vaccine data J.D. Power: Telehealth use boosts members' satisfaction with health plans EFFECTOR Therapeutics bugs out of an IPO, taking the SPAC path with Locust Walk

Featured Story

J&J homes in on manufacturing restart at Emergent plant behind 15M discarded COVID-19 doses

By Fraiser Kansteiner

With production on pause and millions of COVID-19 vaccine doses in limbo, Johnson & Johnson has been hustling to right the ship at CDMO Emergent BioSolutions' troubled Baltimore manufacturing facility. Now, it looks like relief is in sight.

Webinar: The Virtual Sales Rep - Using AI-Powered Bots to Enhance HCP Reach and Engagement

Thursday, June 10 | 1pm ET / 10am PT

Healthcare is becoming more more virtual and digital healthcare tools more common, which presents new challenges and opportunities for pharma sales. In this session, you’ll hear from leading agency experts working to transform HCP experiences with conversational AI voice and chatbots. Register Now.

More than just a step-tracker, smartwatches can predict blood test results and infections, study finds

By Conor Hale

The smartwatch on your wrist already reminds you to get more steps in throughout the day, alerts you to new emails and even takes regular pulse readings—but its insights aren’t skin-deep.

Working remotely helped FDA's CDER shape a new and improved workforce, director says. What now?

By Kevin Dunleavy

The pandemic's work-from-home ethos helped the FDA's Center for Drug Evaluation and Research retain talented employees and attract new ones, forcing the organization to reimagine its future, according to director Patrizia Cavazzoni.

UPDATED Coronavirus tracker: Most unvaccinated people say new CDC mask guidelines aren't enough of an incentive

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

COVID-19 tracker: J&J shot authorized in UK, Mexico; China's Sinopharm releases long-awaited vaccine data

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

Johnson & Johnson is nearing a deal with the FDA to begin producing shots at Emergent's troubled plant in Baltimore. Meanwhile, the U.K. and Mexico authorized the drugmaker's single-shot vaccine. China's Sinopharm released long-awaited data on its vaccines. And more headlines.

J.D. Power: Telehealth use boosts members' satisfaction with health plans

By Paige Minemyer

Increased telehealth use under the pandemic is encouraging members to engage more with their health plans, according to a new report from J.D. Power.

EFFECTOR Therapeutics bugs out of an IPO, taking the SPAC path with Locust Walk

By Kyle LaHucik

EFFECTOR Therapeutics thinks it can be effective in clinical trial advancement following SPAC merger with Locust Walk

Webinar: Getting from R&D to IND - Pitfalls to avoid and how to succeed

Monday, June 28 | 1pm ET / 10am PT

The road to IND isn’t always easy. Balancing speed, risk, and future needs is a challenge. Join to learn how you can take your molecule from discovery through to FiH trials, balancing risk and accelerated timelines while ensuring a stable foundation for future scale-up and commercialization. Register Now.

Deel deze op

Laden...

Andere nieuwsbrieven van Fiercebiotech.com

| 11.26.24 | Amgen’s ph. 2 obesity data disappoint inv estors; Roche buys Poseida for $1.5B while TIGIT flops Fiercebiotech.com
een uur geleden
The Future of Oncology Unveiled Fiercebiotech.com
3 uren geleden
| 11.25.24 | Pfizer leads Big Pharma's Q3 sales sur ge; Cassava ends Alzheimer’s trial after ph. 3 flop Fiercebiotech.com
21 uren geleden

Meer nieuwsbrieven van Fiercebiotech.com

Laden...

COVID-19 Tracker

Featured Story

J&J homes in on manufacturing restart at Emergent plant behind 15M discarded COVID-19 doses

Top Stories

More than just a step-tracker, smartwatches can predict blood test results and infections, study finds

Working remotely helped FDA's CDER shape a new and improved workforce, director says. What now?

UPDATED Coronavirus tracker: Most unvaccinated people say new CDC mask guidelines aren't enough of an incentive

COVID-19 tracker: J&J shot authorized in UK, Mexico; China's Sinopharm releases long-awaited vaccine data

J.D. Power: Telehealth use boosts members' satisfaction with health plans

EFFECTOR Therapeutics bugs out of an IPO, taking the SPAC path with Locust Walk

| 05.28.21 | J&J near FDA deal on Emergent plant restart; CDC mask guidelines not enough to motivate unvaccinated

COVID-19 Tracker

Featured Story

J&J homes in on manufacturing restart at Emergent plant behind 15M discarded COVID-19 doses

Top Stories

More than just a step-tracker, smartwatches can predict blood test results and infections, study finds

Working remotely helped FDA's CDER shape a new and improved workforce, director says. What now?

UPDATED Coronavirus tracker: Most unvaccinated people say new CDC mask guidelines aren't enough of an incentive

COVID-19 tracker: J&J shot authorized in UK, Mexico; China's Sinopharm releases long-awaited vaccine data

J.D. Power: Telehealth use boosts members' satisfaction with health plans

EFFECTOR Therapeutics bugs out of an IPO, taking the SPAC path with Locust Walk

Deel deze op

Andere nieuwsbrieven van Fiercebiotech.com

Gerelateerde nieuwsbrieven